KR20180097542A - 그룹 ii 대사성 글루타메이트 수용체의 알로스테릭 조절제로서의 치환된 트리사이클릭 1,4-벤조디아제피논 유도체 - Google Patents

그룹 ii 대사성 글루타메이트 수용체의 알로스테릭 조절제로서의 치환된 트리사이클릭 1,4-벤조디아제피논 유도체 Download PDF

Info

Publication number
KR20180097542A
KR20180097542A KR1020187016380A KR20187016380A KR20180097542A KR 20180097542 A KR20180097542 A KR 20180097542A KR 1020187016380 A KR1020187016380 A KR 1020187016380A KR 20187016380 A KR20187016380 A KR 20187016380A KR 20180097542 A KR20180097542 A KR 20180097542A
Authority
KR
South Korea
Prior art keywords
alkyl
benzo
cyclopropane
diazepine
spiro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187016380A
Other languages
English (en)
Korean (ko)
Inventor
스테판 섄
스타니슬라스 메이어
바티스트 망투
Original Assignee
마발론 테라퓨틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 마발론 테라퓨틱스 리미티드 filed Critical 마발론 테라퓨틱스 리미티드
Publication of KR20180097542A publication Critical patent/KR20180097542A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
KR1020187016380A 2015-11-13 2016-11-11 그룹 ii 대사성 글루타메이트 수용체의 알로스테릭 조절제로서의 치환된 트리사이클릭 1,4-벤조디아제피논 유도체 Ceased KR20180097542A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15194611 2015-11-13
EP15194611.8 2015-11-13
PCT/GB2016/053550 WO2017081483A1 (en) 2015-11-13 2016-11-11 Substituted tricyclic 1,4-benzodiazepinone derivatives as allosteric modulators of group ii metabotropic glutamate receptors

Publications (1)

Publication Number Publication Date
KR20180097542A true KR20180097542A (ko) 2018-08-31

Family

ID=54542126

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187016380A Ceased KR20180097542A (ko) 2015-11-13 2016-11-11 그룹 ii 대사성 글루타메이트 수용체의 알로스테릭 조절제로서의 치환된 트리사이클릭 1,4-벤조디아제피논 유도체

Country Status (10)

Country Link
US (1) US11008323B2 (enExample)
EP (1) EP3374360A1 (enExample)
JP (1) JP7100362B2 (enExample)
KR (1) KR20180097542A (enExample)
CN (1) CN108834415B (enExample)
AU (1) AU2016354661B2 (enExample)
BR (1) BR112018009550A2 (enExample)
CA (1) CA3004680A1 (enExample)
IL (1) IL259214B (enExample)
WO (1) WO2017081483A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110769830A (zh) * 2017-05-12 2020-02-07 马瓦隆治疗有限公司 作为ii组代谢型谷氨酸受体的别构调节剂的取代的杂环化合物
CN108084187A (zh) * 2017-12-15 2018-05-29 宜昌人福药业有限责任公司 苯并二氮杂*类氢化物
CN108003164A (zh) * 2017-12-15 2018-05-08 宜昌人福药业有限责任公司 苯并二氮杂*类化合物
WO2020223701A1 (en) * 2019-05-02 2020-11-05 The Broad Institute, Inc. Methods for treating neurodevelopmental disorders
CN110172068A (zh) * 2019-06-05 2019-08-27 河南龙湖生物技术有限公司 具有抗肿瘤活性的苯并噻唑类化合物及其制备方法和应用
WO2021226208A2 (en) 2020-05-05 2021-11-11 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
KR102698413B1 (ko) 2020-05-05 2024-08-26 뉴베일런트, 아이엔씨. 헤테로방향족 거대환식 에터 화학치료제
TW202320768A (zh) 2021-10-01 2023-06-01 美商努法倫特公司 雜芳族大環醚化合物之固體形式、醫藥組成物及製備
WO2026006700A1 (en) * 2024-06-28 2026-01-02 Regents Of The University Of Michigan Pyrrolo[1,2-a]-azocine analogues as iap antagonists
CN118993997A (zh) * 2024-10-23 2024-11-22 浙江雅辰药物科技股份有限公司 一种3-溴-2-苯基吡啶的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4130716A (en) 1977-03-07 1978-12-19 Hoffmann-La Roche Inc. Pyrazolo benzodiazepines
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3486459D1 (de) 1983-09-26 1997-12-11 Udo Dr Med Ehrenfeld Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
FI880814A7 (fi) 1987-03-10 1988-09-11 Hoffmann La Roche Imidazodiazepin-derivat.
MX2009007053A (es) 2006-12-28 2009-07-09 Abbott Lab Inhibidores de poli (adp-ribosa) polimerasa.
US10059671B2 (en) 2013-02-04 2018-08-28 Prexton Therapeutics Sa Positive allosteric modulators of mGluR3

Also Published As

Publication number Publication date
US20180346468A1 (en) 2018-12-06
JP2019504108A (ja) 2019-02-14
BR112018009550A2 (pt) 2018-11-06
EP3374360A1 (en) 2018-09-19
JP7100362B2 (ja) 2022-07-13
AU2016354661B2 (en) 2020-12-10
IL259214B (en) 2021-09-30
CA3004680A1 (en) 2017-05-18
CN108834415B (zh) 2021-12-24
IL259214A (en) 2018-07-31
AU2016354661A1 (en) 2018-06-07
US11008323B2 (en) 2021-05-18
WO2017081483A1 (en) 2017-05-18
CN108834415A (zh) 2018-11-16

Similar Documents

Publication Publication Date Title
CN108834415B (zh) 作为ii组代谢型谷氨酸受体的别构调节剂的取代的三环1,4-苯并二氮杂䓬酮衍生物
KR102614872B1 (ko) Hpk1 억제제 및 이의 사용 방법
JP5806672B2 (ja) 新規オキシム誘導体及び代謝型グルタミン酸受容体のアロステリック調節因子としての利用
CN115605475B (zh) 一种免疫抑制剂、其制备方法和应用
TW202419090A (zh) Nlrp3炎症小體抑制劑及其應用
JP2021519316A (ja) Ｔｌｒ２シグナル伝達の調節剤としての化合物
WO2017155050A1 (ja) 芳香環化合物
WO2016104434A1 (ja) 複素環化合物
JP2017507967A (ja) Ｐｅｒｋ阻害剤として作用する化合物
TW201309669A (zh) 吡唑啶－３－酮衍生物
CA3178798A1 (en) 3-((1h-pyrazol-4-yl)methyl)-6'-(phenyl)-2h-(1,2'-bipyridin)-2-one derivatives and related compounds as gpr139 antagonists for use in a method of treatment of e.g. depression
CN121591715A (zh) 作为vav1降解剂的二酮联苯基类化合物及其用途
KR20240024077A (ko) Mglu7 수용체의 음성 다른 자리 입체성 조절제로서의 축합된 헤테로사이클 유도체
KR20200035234A (ko) 그룹 ii 대사성 글루타메이트 수용체의 알로스테릭 조절제로서의 치환된 헤테로사이클릭 화합물
CN107223126A (zh) 作为ii组代谢型谷氨酸受体的别构调节剂的取代的吡唑并喹唑啉酮和吡咯并喹唑啉酮
TW201536761A (zh) 取代三嗪酮化合物及ｔ型鈣通道阻斷劑
TWI867137B (zh) 聯苯基氟代雙鍵衍生物及其製備方法和在藥學上的應用
HK1167386A (en) Metabotropic glutamate receptor modulators
TW201307300A (zh) 趨代謝性麩胺酸受體調節劑

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180608

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20210322

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211110

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240201

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240507

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20240201

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I